Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has Forma Therapeutics Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FMTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: FMTX's weekly volatility (10%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how FMTX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how FMTX performed against the US Market.
Long-Term Price Volatility Vs. Market
How volatile is Forma Therapeutics Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWhat Type Of Shareholders Own The Most Number of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Shares?
3 months ago | Simply Wall StWe Think Forma Therapeutics Holdings (NASDAQ:FMTX) Can Afford To Drive Business Growth
5 months ago | Simply Wall StHere's What Forma Therapeutics Holdings, Inc.'s (NASDAQ:FMTX) Shareholder Ownership Structure Looks Like
Is Forma Therapeutics Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate FMTX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate FMTX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: FMTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: FMTX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FMTX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FMTX is good value based on its PB Ratio (4.1x) compared to the US Biotechs industry average (4.2x).
How is Forma Therapeutics Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FMTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FMTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FMTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FMTX's revenue (78.8% per year) is forecast to grow faster than the US market (10.4% per year).
High Growth Revenue: FMTX's revenue (78.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FMTX is forecast to be unprofitable in 3 years.
How has Forma Therapeutics Holdings performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: FMTX is currently unprofitable.
Growing Profit Margin: FMTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if FMTX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare FMTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FMTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-21.9%).
Return on Equity
High ROE: FMTX has a negative Return on Equity (-16%), as it is currently unprofitable.
How is Forma Therapeutics Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: FMTX's short term assets ($415.7M) exceed its short term liabilities ($30.7M).
Long Term Liabilities: FMTX's short term assets ($415.7M) exceed its long term liabilities ($1.1M).
Debt to Equity History and Analysis
Debt Level: FMTX is debt free.
Reducing Debt: FMTX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FMTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: FMTX has sufficient cash runway for 2.7 years if free cash flow continues to grow at historical rates of 22.8% each year.
What is Forma Therapeutics Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FMTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FMTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FMTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FMTX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FMTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Frank Lee (53 yo)
Mr. Frank D. Lee is Chief Executive Officer of FORMA Therapeutics, Inc. since March 27, 2019. Mr. Lee is President and Chief Executive Officer at Forma Therapeutics Holdings, Inc. since joining in March 27...
CEO Compensation Analysis
Compensation vs Market: Frank's total compensation ($USD3.57M) is about average for companies of similar size in the US market ($USD3.68M).
Compensation vs Earnings: Insufficient data to compare Frank's compensation with company performance.
|Senior VP of Corporate Affairs & Chief Human Resources Officer||6.42yrs||US$944.89k||0.24% |
|Senior VP & CFO||1.42yrs||no data||0% |
|Senior VP & Chief Scientific Officer||0.83yr||no data||0% |
|Senior VP||1.42yrs||no data||0.0069% |
|Senior VP & Chief Medical Officer||1.5yrs||no data||0.088% |
|Treasurer||no data||no data||no data|
Experienced Management: FMTX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
|Independent Non-Executive Director||0.42yr||no data||0% |
|Independent Non-Executive Chairman||8.25yrs||no data||0.26% |
|Independent Non-Executive Director||6.33yrs||no data||0.11% |
|Independent Non-Executive Director||2.92yrs||no data||0.048% |
|Independent Non-Executive Director||1.17yrs||no data||0% |
|Independent Non-Executive Director||0.58yr||no data||0% |
|Director||0.083yr||no data||no data|
|Independent Non-Executive Director||5.83yrs||no data||0.093% |
Experienced Board: FMTX's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: FMTX only recently listed within the past 12 months.
Forma Therapeutics Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Forma Therapeutics Holdings, Inc.
- Ticker: FMTX
- Exchange: NasdaqGM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.888b
- Shares outstanding: 48.91m
- Website: https://www.formatherapeutics.com
Number of Employees
- Forma Therapeutics Holdings, Inc.
- 500 Arsenal Street
- Suite 100
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|FMTX||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jun 2020|
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers....
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/02/28 00:11|
|End of Day Share Price||2021/02/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.